Understanding Breast Cancer Subtypes in BRCA Carriers
Part of Cancer, Skin clinical trials.
This study examines how different molecular subtypes (patterns of genes and proteins) of breast cancer behave in people with BRCA1 or BRCA2 mutations. By studying tumor samples and medical records, researchers hope to better predict which treatments will work best and predict long-term outcomes for BRCA-positive breast cancer patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed BRCA1 or BRCA2 genetic mutation (pathogenic or likely pathogenic)
- You have been diagnosed with HR-positive, HER2-negative breast cancer that has been confirmed under a microscope (histologically confirmed)
- Your medical records from the hospital or clinic visits are available for the research team to review
- A preserved tumor tissue sample from your breast cancer (primary tumor or metastatic site) is available for testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study that looks at how different cancer prevention approaches affect women with harmful (deleterious) BRCA1 or BRCA2 mutations. It may help improve future prevention and follow-up plans for women at higher inherited risk.
This study looks at which DNA “repair” gene changes are found in breast cancer patients, especially certain subtypes and high-risk situations. Your genetic test results may help researchers understand who has specific DNA repair pathway mutations and how they relate to breast cancer.
This trial studies your tumor’s gene activity and breast cancer subtype to help guide treatment choices. It mainly looks at whether analyzing “RNA expression” and tumor subtype can improve how therapy is optimized during metastatic breast cancer care.
This study collects blood (and possibly tumor tissue) to learn how certain inherited gene changes relate to breast and ovarian cancer risk. It may help researchers understand which people are most likely to develop these cancers and how tumors differ in high-risk patients.
This study looks at specific DNA “damage repair” proteins as a marker to understand why some BRCA-mutated breast cancers may resist PARP inhibitor treatment. Your biopsy (or existing biopsy) helps researchers study whether these lab markers relate to how well PARP inhibitors work.
This study looks at how often certain BRCA2 gene changes occur in people in Réunion who have breast cancer. Your participation may help doctors understand breast cancer risk in the local community and guide future care.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.